Bicara Therapeutics Inc (BCAX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Bicara Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Bicara Therapeutics Inc (BCAX) has returned 18.18% so far this year and 52.65% over the past 12 months.

Based on dividend-adjusted daily data since Sep 13, 2024, BCAX's average daily return is +0.09%, while the average monthly return is +0.51%. At this rate, your investment would double in approximately 11.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Sep 2025 with a return of +32.2%, while the worst month was May 2025 at -35.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, BCAX closed higher 49% of trading days. The best single day was Sep 29, 2025 with a return of +18.5%, while the worst single day was May 23, 2025 at -40.8%.

Bicara Therapeutics Inc has an annualized alpha of 7.01%, beta of 1.49, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since September 16, 2024.

• This stock participated in 30.16% of S&P 500 Index downside but only -27.32% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BCAX ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Bicara Therapeutics Inc (BCAX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Bicara Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bicara Therapeutics Inc was 67.82%, occurring on Jun 27, 2025. The portfolio has not yet recovered.

The current Bicara Therapeutics Inc drawdown is 26.52%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Bicara Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Bicara Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.